Consumers Want Choice of COVID Vaccines

Americans want COVID-19 vaccines developed from traditional technologies
what's your choice
(Precision Vaccinations News)

More than one year after the first COVID-19 vaccine was administered in the United States, new data from a recent survey conducted online by The Harris Poll show 73% of consumers would like to see additional COVID-19 vaccines become available.

Currently, the World Health Organization has listed ten different COVID-19 vaccines based on various technologies.

But the U.S. FDA has only authorized/approved three COVID-19 vaccines.

Moreover, consumers would like to see COVID-19 vaccines developed from traditional methods, such as technologies used to produce diphtheria, mumps, chickenpox, or polio vaccines.

Other key findings from the survey include, but are limited to the following:

  • 70% of Americans believe it’s essential for children to be vaccinated against COVID-19,
  • 75% of vaccinated Americans agree that if a COVID-19 booster is recommended every six months, they will get it, and
  • 41% of parents with children under age 18 who have not yet vaccinated their children for COVID-19 say they would be more likely to get their child vaccinated if there were a new vaccine that was more effective against multiple variants and emerging variants of concern.

The Harris Poll conducted this survey online within the United States on behalf of Ocugen, Inc. from February 3-7, 2022, among 2,015 adults. This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated.

The Harris Poll is one of the longest-running surveys in the U.S. tracking public opinion and social sentiment since 1963.

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen, Inc., stated in a press release issued on February 15, 2022, “All safe and effective options should be considered to manage the (COVID-19) pandemic.”

Ocugen has partnered with India-based Bharat Biotech and is seeking U.S. FDA and Canada’s authorization to deliver the Covaxin Whole-Virion Inactivated COVID-19 vaccine.

Having delivered more than 4 billion vaccine doses worldwide, Bharat Biotech continues to lead innovation. It has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Click here to learn more about Bharat Biotech.

To learn more about Pennsylvania-based Ocugen, Inc., click here.

PrecisionVaccinations publishes fact-checked, research-based antibody, antiviral, and vaccine news.


Our Trust Standards: Medical Advisory Committee